Where does EyeGate Pharmaceuticals, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), EyeGate Pharmaceuticals, Inc. ranks #40,148 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does EyeGate Pharmaceuticals, Inc. hold?

EyeGate Pharmaceuticals, Inc. holds 6 US utility patents granted between 2015 and 2019, spanning 5 technology areas.

What is EyeGate Pharmaceuticals, Inc.'s Innovation Score?

EyeGate Pharmaceuticals, Inc. has an Innovation Score of 21.8 out of 100 (9th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does EyeGate Pharmaceuticals, Inc. focus on?

EyeGate Pharmaceuticals, Inc.'s top technology area is A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy) with 6 patents, ranking #583 of 1,943 assignees active in that subclass. Grants appear in 5 CPC subclasses total.

Is EyeGate Pharmaceuticals, Inc.'s patent grant rate increasing or decreasing?

EyeGate Pharmaceuticals, Inc.'s recent grant velocity is -100% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for EyeGate Pharmaceuticals, Inc.'s patents?

EyeGate Pharmaceuticals, Inc.'s patents average 12.0 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the EyeGate Pharmaceuticals, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

EyeGate Pharmaceuticals, Inc.

USPTO PatentsView assignee record - 6 granted patents across 5 technology areas, recorded in grant years 2015–2019. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Eyegate ranks #40,148 of 49,997 tracked US assignees by granted-patent volume, with 6 patents across 5 technology areas.

#40,148
of 49,997 US assignees by volume: 9th percentile
by Innovation Score (21.8/100): 12.0
avg claims per patent: -100%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R40148 · US Corporation #40,148 · 6 grants

GRANTS-MICRO · LOWER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-DROP · BOOK-FULL

GRANTS-MICRO 6 grants
LOWER-Q #40,148/49,997
PHOTO-FINISH Exosite
CPC-NARROW A61N · 5 areas
INNOV-THIN 21.8/100
CLAIMS-RICH 12.0 claims/avg
TYPE-USCORP US Corporation
VEL-DROP -100% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Exosite LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Eyegate’s 21.8 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 6.7 pts (31%) Velocity 0.0 pts (0%) Breadth 7.9 pts (36%) Claim depth 7.2 pts (33%)

Qualcomm Incorporated · highest

85
EyeGate Pharmaceutic… · this assignee

22
3D Lighting… · lowest

7

What this shows Eyegate's Innovation Score is 21.8/100 (9th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Eyegate?

Each dot is one of Eyegate’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Eyegate’s own 12.0 claims/patent is at or below the 16.3 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Eyegate vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Eyegate's grants concentrate

EyeGate Pharmaceuticals, Inc. is a focused PatentsView assignee: 5 CPC subclasses with 100% of grants classified under A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy). Peak complete grant year is 2015 (2 grants) versus a trough of 1 in 2018. By volume, Eyegate sits between Exosite LLC and F.F. Seeley Nominees PTY Ltd..

Exosite

6
Expanding Innovat…

6
Expedera

6
Exuma Biotech

6
Eyeprint Prosthet…

6
F & M Tool & Plas…

6
F S Fehrer Automo…

6
F F Seeley Nomine…

6
Eyegate Pharmaceu… ◀

6

What this shows EyeGate holds 6 patents at rank #40,137, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near EyeGate

By rank, the assignees closest to #40,137 in granted patent volume.

Leaders in A61N (Electrotherapy)

Other assignees with the most granted patents in EyeGate's primary technology class.

Eyegate's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

22 9th percentile higher than 9% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2019

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

EyeGate Pharmaceuticals, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	2	33.3%
2017	2	33.3%
2018	1	16.7%
2019	1	16.7%

Which technologies does EyeGate Pharmaceuticals, Inc. patent most?

A61N - ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy 6

A61F - Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive DEVICES; FOMENTATION; Treatment OR Protection OF Eyes OR EARS; Bandages, Dressings OR Absorbent PADS; Firs 6

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 4

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 3

G02C - SPECTACLES; Sunglasses OR Goggles Insofar AS They Have THE Same Features AS SPECTACLES; Contact Lenses 1

Top 5 of 5 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

EyeGate Pharmaceuticals, Inc.'s patent record in context - here's where to go next.

EyeGate Pharmaceuticals, Inc.'s lead technology class is A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy), 100% of its portfolio - see every assignee active in that class. Explore A61N
Ranked #40,148 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare EyeGate Pharmaceuticals, Inc. against Exosite LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 21.8/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.